Search results for "REAL-WORLD"

showing 10 items of 49 documents

An evaluation of recent local image descriptors for real-world applications of image matching

2019

This paper discusses and compares the best and most recent local descriptors, evaluating them on increasingly complex image matching tasks, encompassing planar and non-planar scenarios under severe viewpoint changes. This evaluation, aimed at assessing descriptor suitability for real-world applications, leverages the concept of approximated overlap error as a means to naturally extend to non-planar scenes the standard metric used for planar scenes. According to the evaluation results, most descriptors exhibit a gradual performance degradation in the transition from planar to non-planar scenes. The best descriptors are those capable of capturing well not only the local image context, but als…

Settore ING-INF/05 - Sistemi Di Elaborazione Delle InformazioniSettore INF/01 - InformaticaImage matchingComputer sciencebusiness.industryVisual descriptorsComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISIONPattern recognition02 engineering and technology03 medical and health sciences0302 clinical medicineLocal Image Descriptors; Image MatchingRobustness (computer science)Computer Science::Computer Vision and Pattern RecognitionComputer Science::Multimedia030221 ophthalmology & optometry0202 electrical engineering electronic engineering information engineering020201 artificial intelligence & image processingArtificial intelligencebusinessImage matching Data-driven approach Descriptors Evaluation results Local descriptors Local image descriptors Performance degradation Real-worldScene structure Computer vision
researchProduct

Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study

2021

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) affects around 60% of patients with severe eosinophilic asthma (SEA). Benralizumab was recently approved for SEA add-on treatment. Objective: To assess the real-world effectiveness of benralizumab in SEA with or without CRSwNP. Methods: We conducted a multicenter observational study, including patients with SEA treated with benralizumab for 24 weeks in 12 Italian specialized facilities. Asthma exacerbations, Asthma Control Test (ACT), lung function, oral corticosteroid (OCS) dosage, and eosinophil and basophil count in peripheral blood were recorded at baseline and after 4, 12, and 24 weeks. The 22-item Sino-Nasal Outcome Test (S…

Severe asthmaVital capacitymedicine.medical_specialtymedicine.drug_classSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedFEV1/FVC ratiochemistry.chemical_compoundNasal PolypsInternal medicinemedicineHumansImmunology and AllergyNasal polypsAnti-Asthmatic AgentsIL-5Nasal polypbusiness.industryMinimal clinically important differenceBenralizumabFunctional endoscopic sinus surgeryrespiratory systemEosinophilBenralizumabmedicine.diseaseAsthmaChronic rhinosinusitismedicine.anatomical_structureReal-worldchemistryChronic rhinosinusitiCorticosteroidbusinessHumanThe Journal of Allergy and Clinical Immunology: In Practice
researchProduct

Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setti…

2021

Immune checkpoint inhibitors (ICIs) are the new frontier for the treatment of advanced hepatocellular carcinoma (HCC). Since the first trial with tremelimumab, a cytotoxic T-lymphocyte-associated protein 4 inhibitor, increasing evidence has confirmed that these drugs can significantly extend the survival of patients with advanced hepatocellular carcinoma (HCC). As a matter of fact, the overall survival and objective response rates reported in patients with advanced HCC treated with ICIs are the highest ever reported in the second-line setting and, most recently, the combination of the anti-programmed death ligand protein-1 atezolizumab with bevacizumab—an anti-vascular endothelial growth fa…

SorafenibOncologymedicine.medical_specialtyBevacizumabPopulationSystemic treatmentReviewunresectable hepatocellular carcinoma03 medical and health sciences0302 clinical medicineAtezolizumabInternal medicinemedicineeducationSettore MED/12 - Gastroenterologiaeducation.field_of_studybusiness.industryRGeneral Medicinemedicine.diseaseUnresectable hepatocel-lular carcinomaRegimenReal-world030220 oncology & carcinogenesisHepatocellular carcinomaMedicine030211 gastroenterology & hepatologyImmunotherapybusinessLiver cancerImmunotherapy; Liver cancer; Real-world; Systemic treatment; Unresectable hepatocel-lular carcinomaLiver cancerTremelimumabmedicine.drugJournal of Clinical Medicine
researchProduct

Large‐scale set partitioning problems: Some real‐world instances hide a beneficial structure

2006

In this paper we consider large‐scale set partitioning problems. Our main purpose is to show that real‐world set partitioning problems originating from the container‐trucking industry are easier to tackle in respect to general ones. We show such different behavior through computational experiments: in particular, we have applied both a heuristic algorithm and some exact solution approaches to real‐world instances as well as to benchmark instances from Beasley OR‐library. Moreover, in order to gain an insight into the structure of the real‐world instances, we have performed and evaluated various instance perturbations. Didelės matematinės aibės dalijimo problemų sprendimas, nagrinėjant reali…

Structure (mathematical logic)Mathematical optimizationLagrangian relaxationHF5001-6182real-world instancesEconomic growth development planningScale (descriptive set theory)set partitioningSet (abstract data type)symbols.namesakecontainer-trucking industryinstance perturbationsOR-libraryLagrangian relaxationHD72-88Benchmark (computing)symbolsBusinessFinanceMathematicsTechnological and Economic Development of Economy
researchProduct

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substit…

2019

Background: The importance of alcohol and cannabis consumption for the effectiveness of treatment of chronic hepatitis C virus (HCV) infection with direct acting antivirals (DAAs) in people on opioid substitution therapy (OST) has not been investigated in detail. Methods: We investigated sustained virological response (SVR) rates and proportion of lost to follow-up (LTFU) between OST (n = 739) and non-OST patients (n = 7008) in the German Hepatitis C-Registry (Deutsches Hepatitis C-Register, DHC-R), which is a national multicenter prospective non-interventional real-world registry. Non-OST patients comprised patients with former/current drug use (non-OST/DU; n = 1500) and patients never con…

cannabismedicine.medical_specialtyMedizinShort ReportAlcoholVirus03 medical and health scienceschemistry.chemical_compound0302 clinical medicineChronic hepatitisInternal medicinereal-world settingmedicine030212 general & internal medicinePWIDConsumption (economics)biologyOSTbusiness.industryalcohollcsh:Public aspects of medicinefungilcsh:RA1-1270Hepatitis Cbiology.organism_classificationmedicine.diseaseSVR12Psychiatry and Mental healthchemistryCohortHCV030211 gastroenterology & hepatologyCannabisbusinessOpioid substitution therapySubstance abuse : research and treatment
researchProduct

Adherence to omalizumab: A multicenter “real-world” study

2020

Background: Adherence to medications is crucial in patients with severe asthma in light of the negative clinical impact and costs of non-adherence. Adherence to omalizumab has not been well studied in real-world settings. The aim of this study was to assess adherence to omalizumab and evaluate treatment effectiveness in relation to adherence. Methods: This was a retrospective, observational, and multicenter real-world study. Omalizumab dose, timing of administration, and duration of treatment ( 4 years) were analyzed. Adherence was evaluated by examining rates of expected and missing doses. Good adherence (10% doses missed) were determined. For effectiveness in relation to adherence of omal…

lcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaEfficacySevere asthmaImmunologyOmalizumabOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioArticlePoor adherence03 medical and health sciences0302 clinical medicineInternal medicineImmunology and AllergyMedicineIn patient030223 otorhinolaryngologyAsthmaAsthma exacerbationsbusiness.industrySevere asthma Omalizumab Adherence Efficacy Real-worldmedicine.disease030228 respiratory systemReal-worldAdherenceObservational studylcsh:RC581-607businessAsthma Control Testmedicine.drug
researchProduct

Kidney Disease Management in the Hospital Setting: A Focus on Inappropriate Drug Prescriptions in Older Patients

2021

Aging with multimorbidity and polytherapy are the most significant factors that could led to inappropriate prescribing of contraindicated medications in patients with chronic kidney disease (CKD). The aim of this study was to evaluate the prescriptions of contraindicated drugs in older adults in CKD and to identify their associated factors in a hospital context. An observational retrospective study was carried out considering all patients ≥65 years with at least one serum creatinine value recorded into the REPOSI register into 2010–2016 period. The estimated glomerular filtration rate (eGFR) was applied to identify CKD. A descriptive analysis was performed to compare demographic and clinica…

medicine.medical_specialtyappropriateness of prescriptionprescribing patternsRenal functionContext (language use)RM1-950Logistic regressionNOchemistry.chemical_compoundolder patientInternal medicinehospital settingmedicinePharmacology (medical)LS4_4Medical prescriptionprescribing patternappropriateness of prescriptions chronic kidney disease hospital setting older patients prescribing patterns real-world data.Original ResearchPharmacologyCreatininereal-world databusiness.industryRetrospective cohort studymedicine.diseaseolder patientsreal-world data.appropriateness of prescriptions; chronic kidney disease; hospital setting; older patients; prescribing patterns; real-world dataappropriateness of prescriptionschemistryObservational studyTherapeutics. Pharmacologybusinesschronic kidney diseaseKidney diseaseFrontiers in Pharmacology
researchProduct

A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Bi…

2020

Purpose There has been an increasing clinical interest in specific retinal parameters as non-invasive biomarkers of retinal inflammation in diabetic macular edema (DME) that have been shown to have prognostic value, such as hyperreflective retinal fields (HRFs) and subfoveal neuroretinal detachment (SND). Methods We conducted a prospective, non-comparative study of treatment-naive patients with DME to evaluate the efficacy of a Pro Re Nata (PRN) regimen of intravitreal dexamethasone implant 0.7 mg (DexI, Ozurdex™). After administration, patients underwent subsequent injections according to PRN criteria in case of edema relapse, but not earlier than 4 months after the previous treatment. Pat…

medicine.medical_specialtyreal-worldVisual acuitygenetic structures03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePro re nataDexamethasone implant Diabetic macular edema Inflammation Intravitreal implants Ozurdex Real-worldEdemaOphthalmologymedicinedexamethasone implantAdverse effectDexamethasoneOriginal Researchbusiness.industrySettore MED/30 - Malattie Apparato VisivoRetinaleye diseasesOphthalmologyRegimenintravitreal implantschemistryinflammationOzurdex030221 ophthalmology & optometryImplantsense organsmedicine.symptombusinessdiabetic macular edema030217 neurology & neurosurgerymedicine.drugClinical ophthalmology (Auckland, N.Z.)
researchProduct

Treatment-resistant depression in a real-world setting: first interim analysis of characteristics, healthcare resource use, and utility values of the…

2020

Background: Major depressive disorder (MDD) is among the most common psychiatric disorders. One-third of patients are usually unresponsive to several lines of treatment. This study aimed to describe the FondaMental French cohort of patients with treatment-resistant depression (TRD) and to estimate utility and healthcare resource use outcomes. Methods: Patients with TRD were evaluated prospectively over four years (baseline, 6, 12, 18, 24, 36 and 48 months) in a real-world clinical setting. Interim analyses focused on the first two consecutive years. Four MDD-related states (major depressive episode (MDE), response, remission, recovery) were defined based on the MADRS (Montgomery&ndash

medicine.medical_specialtyreal-world[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthArticlelcsh:RC321-57103 medical and health sciences0302 clinical medicinehealthcare resource useQuality of lifeRating scaleInternal medicineMedicine[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Major depressive episodelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryDepression (differential diagnoses)business.industryGeneral Neurosciencemedicine.diseaseInterim analysis3. Good health030227 psychiatryutility[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthCohorttreatment-resistant depressionMajor depressive disorder[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC][SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiemedicine.symptombusinessTreatment-resistant depression030217 neurology & neurosurgery
researchProduct

Pharmacokinetics of new oral anticoagulants: implications for use in routine care

2018

Introduction: Since 2008, new oral anticoagulants (NOACs) have been approved for the prevention of venous thromboembolism (VTE) in patients receiving hip or knee replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Premarketing randomized clinical trials (RCTs) of NOACs demonstrated their non-inferiority in terms of efficacy vs. warfarin (traditional oral anticoagulant–TOA), with lower risk of serious adverse drug reactions, especially cerebral hemorrhages. In clinical practice, pharmacokinetic aspects of NOACs have to be carefully taken into account to …

medicine.medical_treatmentnew oral anticoagulantsAdministration OralKnee replacement030204 cardiovascular system & hematologyToxicologyAdherence Bleeding Interactions New oral anticoagulants Over- and under-dosage Persistence Pharmacokinetics Real World Evidence0302 clinical medicineAtrial Fibrillationover- and underdosage030212 general & internal medicinepharmacokineticStrokeRoutine careRandomized Controlled Trials as Topicnew oral anticoagulantAtrial fibrillationpersistenceVenous ThromboembolismGeneral MedicinePulmonary embolismStrokepharmacokineticsHumanmusculoskeletal diseasesmedicine.medical_specialtyinteractionHemorrhageMedication Adherence03 medical and health sciencesPharmacokineticsmedicineHumansReal World EvidenceIn patientOver- and under-dosagecardiovascular diseasesreal-world evidenceIntensive care medicineAgedPharmacologybusiness.industryAnticoagulantAnticoagulantsinteractionsbleedingmedicine.diseaseAdherencePulmonary EmbolismbusinessVenous thromboembolismExpert Opinion on Drug Metabolism & Toxicology
researchProduct